Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 801 - 850 out of 12,317

Document Document Title
WO/2011/083484A3
The present invention relates to improved process for the preparation of lamivudine or emtricitabine. Thus, (1'R,2'S,5'R)-menthyl- 5(R,S)-acetoxy-[1,3]-oxathiolane-2(R)-carboxylate is reacted with N-propinoyl cytosine in hexamethyl disil...  
WO/2012/175516A1
The present invention concerns a new family of analogues of NADP+ or NADPH, their preparation and their application in therapeutics.  
WO/2012/143624A3
The invention relates to acadesine derivatives as a drug, as well as to said derivatives for the treatment of cancer and particularly for the treatment of chronic myeloid leukemia (CML). The invention further relates to a product contain...  
WO/2012/170347A1
The present invention provides novel bicyclic nucleosides and oligomeric compounds prepared therefrom. Incorporation of one or more of the bicyclic nucleosides into an oligomeric compound is expected to enhance one or more properties of ...  
WO/2012/168348A1
The application provides methods for treatment or prophylaxis of dengue virus mediated diseases with compounds of Formula I wherein R1, R2a, R2b, R3, R4, R5 R6, R8a, R9 and R10 are as defined herein. The application further discloses met...  
WO/2012/166705A2
Described herein are hydrogelators that include a nucleobase, an amino acid, and a glycoside. The hydrogelators have increased resistance to proteases and can self-assemble into supramolecular nanofibers or hydrogels. The supramolecular ...  
WO/2012/164484A1
New derivatives of adenosine and deoxyadenosine modified at position 8 of the purine ring, of general formula (I) are described, which are suitable to be conjugated with functional molecules such as chromophores, fluorophores and interca...  
WO/2012/161948A1
The present invention comprises novel conjugates and immunogens derived from gemcitabine and unique antibodies generated by using gemcitabine linked immunogens, which conjugates immunogens and antibodies, are useful in immunoassays for t...  
WO/2012/159047A1
The invention provides synthetic processes and synthetic intermediates that can be used to prepare compounds having useful anti-HIV properties.  
WO/2012/158197A2
Compounds, and pharmaceutical compositions, and formulations thereof, are disclosed that have formula (I): where R1a, R1b, R1c, R2, R3, R6a, R6b, R6c, R7, and R8 are as defined herein. The compounds, pharmaceutical compositions, and phar...  
WO/2012/155824A1
Disclosed are compounds of formula(I),pharmaceutically acceptable salts and solvates thereof, wherein R can be COOR1,in which R1 can be H, substituted or unsubstituted C1~C10 straight chain or straight chain alkyl; preferred H, substitut...  
WO/2012/158811A2
The present invention is directed to compounds, compositions and methods for treating or preventing viral infections using nucleoside analog monophosphate prodrugs. More specifically, HCV, Norovirus, Saporovirus, Dengue virus, Chikunguny...  
WO/2012/154321A1
Provided herein are compounds, compositions and methods for the treatment of liver disorders, including HCV infections. In one embodiment, compounds and compositions of nucleoside derivatives are disclosed, which can be administered eith...  
WO/2011/003018A9
Disclosed are halogenated 2-deoxy-lactone, 2'-deoxy-nucleosides, and derivatives thereof, for example, a compound of formula (I). Also disclosed are a composition comprising a pharmaceutically acceptable carrier and at least one compound...  
WO/2012/148998A1
The present invention relates to a pharmaceutical or dietary composition comprising deoxyuridine and a pharmaceutically or dietetically suitable carrier. Another aspect of the present invention relates to a method of supplementing the di...  
WO/2012/149196A1
This disclosure relates to an improved process for the preparation of regadenoson, pharmaceutically acceptable salts thereof, and hydrates thereof, and for the preparation of intermediates useful in the synthesis of regadenoson. The disc...  
WO/2012/143624A2
The invention relates to acadesine derivatives as a drug, as well as to said derivatives for the treatment of cancer and particularly for the treatment of chronic myeloid leukemia (CML). The invention further relates to a product contain...  
WO/2012/139227A1
The present invention provides a method of preventing or treating cardiovascular dysfunction by administering a therapeutically effective amount of (a) one or more of (i) S-adenosylmethionine or a derivative or pharmaceutically acceptabl...  
WO/2012/140596A1
The present invention provides a compound of formula I; a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a ph...  
WO/2012/142523A2
Provided are compounds of Formula I: nucleosides, nucleoside phosphates and prodrugs thereof, wherein R6 is CN, ethenyl, 2- haloethen-1-yl, or (C2-C8)-alkyn-1-yl. The compounds, compositions, and methods provided are useful for the treat...  
WO/2012/136604A1
The present invention relates to photoactivable protecting groups containing a diarylsulphid chromophore, a method for the synthesis thereof and their use as photoactivable protecting groups using maskless photolithography based array sy...  
WO/2012/138530A1
Disclosed are O-protected compounds of the formula (I):wherein B is an optionally protected nucleobase, and R1-R3 are as described herein, a method of preparing such compounds, and a method of preparing oligonucleotides such as RNA start...  
WO/2012/129651A1
The invention provides compounds of formula (I) with substituents as specified in claim 1 for selectively inhibiting glycosidases, prodrugs of the compounds, and pharmaceuticals compositions including the compounds or prodrugs of the com...  
WO/2012/135405A1
Provided herein are processes for the preparation of 5-azacytidine, useful for treating, preventing, and/or managing diseases or conditions including cancer, disorders related to abnormal cell proliferation, hematologic disorders, and my...  
WO/2012/130238A1
The present invention provides a novel modified oligonucleotide monomer useful in molecular biological techniques such as capture and/or detection of nucleic acids, amplification of nucleic acids and sequencing of nucleic acids. The modi...  
WO/2012/078416A3
The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV and HBV, in human patients or other animal hosts. The compounds are certain 6-substituted...  
WO/2012/075500A3
Disclosed are compounds, pharmaceutical compositions containing the compounds, uses of the compounds and compositions as modulators of histone methyltransf erases, and methods for treating diseases influenced by modulation of histone met...  
WO/2012/082436A3
Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone meth...  
WO/2011/113476A3
(A) reacting the alkali metal salt of 2, 6-dichlorpurine with a 2-desoxy-3, 5 -di-O-p-toluoyl-alpha-D-erythro-pentofuranose or a derivative thereof, in a suitable organic solvent, said reaction optionally being carried out in the presenc...  
WO/2012/115249A1
The present invention provides a novel crystalline form of 1,1-anhydro-1-C-[5-(4-ethylphenyl)methyl-2-(hydroxyl- methyl)phenyl]-β-D-glucopyranose, which has a peak at a diffraction angle (2θ) around 4.0˚ in a powder X-ray diffraction ...  
WO/2012/115578A1
The present invention concerns the synthesis of substantially anomerically pure 2,3-dideoxy-3- fluoro-5-0-(4-phenylbenzoyl)-a-D-erythropentofuranosyl chloride from an α/β-mixture of the corresponding methyl glycoside. The method of the...  
WO/2012/103807A1
The present invention belongs to the technical field of pharmaceuticals. Disclosed are a bifunctional anti-platelet aggregation medicament represented by formula (I) and its uses for preventing and treating arterial thrombotic diseases. ...  
WO/2010/075549A3
A nucleoside compound having activity against hepatitis C virus is disclosed.  
WO/2012/105542A1
The present invention addresses the problem of providing an external preparation for the skin having a sustainable antiwrinkle effect, which has an action of promoting the proliferation and differentiation of keratinocytes and an action ...  
WO/2012/100654A1
The present invention relates to compounds represented by General Formulas (I) and (I-1), and a preparation method therefor, a use of the compounds in treatment of platelet aggregation-related diseases and in preparation of drugs for tre...  
WO/2012/011114A3
The present invention provides specific double-stranded DNA/RNA binding compounds having a polymeric structure, which are in fact, triplex forming molecules capable of binding tightly and specifically to predetermined sequences in the ma...  
WO/2012/048202A3
The invention is directed to processes for synthesizing bicyclic nucleoside antiviral compounds and for synthesizing the intermediates used in the process. The invention is also directed to novel intermediate compounds useful in the proc...  
WO/2012/096596A1
The invention relates to a combination of bis-(gamma-L-glutamyl)-L-cysteinyl-glycine or a salt thereof, inosine and coordination compounds formed by palladium, copper and (gamma-L-glutamyl)-L-cysteinyl-glycine, as well as to a pharmaceut...  
WO/2012/090136A1
The present invention relates to compounds of formula (I): wherein Rj, R2, R3, R4, Xi, X2, X3 and Z are as defined in claim 1. The compounds are useful in the prevention and/or treatment of bacterial infections.  
WO/2012/090155A1
We claim a simple strategy for the synthesis of a collection of C(3')-spirodihydroisobenzo- furannulated and C(3')-spirodihydroisobenzo-furannulated nucleosides featuring a [2+2+2]- cyclotrimerization as the key reaction. The cyclotrimer...  
WO/2012/091091A1
A compound which is characterized by being represented by formula (1), (2) or (3). (In formulae (1), (2) and (3), Z11 and Z12 each independently represents a fluorescent atomic group that has an exciton effect and does not have an electr...  
WO/2009/064387A3
The invention provides for novel 2-Deoxyadenosine compounds, which can treat HIV infection at low cytotoxicity values. Substitution at the 4 '-position provided compounds which demonstrated low cytotoxicity values in an ATP -based cytoto...  
WO/2012/088155A1
Disclosed herein are cyclic nucleotide analogs, methods of synthesizing cyclic nucleotide analogs and methods of treating diseases and/or conditions such as viral infections, cancer, and/or parasitic diseases with cyclic nucleotide analogs.  
WO/2010/075517A3
A purified compound having activity against hepatitis C virus is disclosed.  
WO/2012/082436A2
Disclosed are compounds, pharmaceutical compositions containing the compounds, and the uses of the compounds and compositions as modulators of histone methyltransferases, and for treating diseases influenced by modulation of histone meth...  
WO/2012/048013A3
This invention is directed to novel compounds of formula (I) having the structure that are useful in the treatment of viral infections in mammals mediated, at least in part, by a virus in the Flaviviridae family of viruses. Methods of tr...  
WO/2012/078416A2
The present invention is directed to compounds, compositions and methods for treating or preventing cancer and viral infections, in particular, HIV and HBV, in human patients or other animal hosts. The compounds are certain 6-substituted...  
WO/2012/077800A1
Provided is a technique for detecting 8-oxo-dG in DNA with the use of a novel compound represented by formula (I). In formula (I): R1 represents a hydrogen atom, a protecting group for the 3'-hydroxyl group, an oligodeoxynucleotide group...  
WO/2012/075959A1
Disclosed are a hemi-methylation linker, a method for determining the methylation information in a sample DNA and a kit. The semi-methylation linker has a first strand and a second strand, wherein the cytosines in the first strand are al...  
WO/2012/073217A1
The present invention provides a process for the preparation of a morpholinyl anthracycline derivative in good yields and purity, including 3'-deamino-3"-4'-anhydro- [2"(S)-methoxy-3"(R)-hydroxy-4"-morpholinyl] doxorubicin (1).  

Matches 801 - 850 out of 12,317